Zacks Investment Ideas feature highlights: Quantum Computing, D-WAVE QUANTUM and IonQ
The quantum computing industry has seen a surge of attention in 2025, driven by a wave of technical breakthroughs and a rapid expansion in real-world applications. Once viewed as a far-off moonshot, quantum technology is now making tangible strides, with implications for cybersecurity, drug discovery, AI, and more. As investor interest accelerates, several quantum stocks appear poised for major breakouts.
Three quantum stocks in particular stand out right now: Quantum Computing Inc., D-WAVE QUANTUM and IonQ. Each is benefiting from strong price momentum and rising earnings estimates, key ingredients for breakout potential. On top of that, all three are forming bullish technical patterns that suggest the possibility of another major run in the near term.
D-WAVE QUANTUM has emerged as a clear leader in the quantum computing space, with its stock gaining more than 1,000% since last fall. The company specializes in quantum annealing, a unique approach to quantum computing that is already being applied to real-world optimization problems in logistics, manufacturing, and AI.
Currently holding a Zacks Rank #2 (Buy), D-Wave is benefiting from a wave of bullish sentiment, as analysts have unanimously raised earnings estimates. While the company remains unprofitable, its top-line growth trajectory is impressive, as sales are expected to surge 183% this year, followed by another 62% increase in 2026.
From a technical perspective, QBTS is forming a bullish descending wedge pattern—a setup often associated with strong breakout potential. If the stock can break through resistance at the $14.70 level, it could trigger another explosive move to the upside, reinforcing its position as the momentum leader in the quantum space.
Quantum Computing Inc. has emerged as one of the stronger performers in the quantum computing sector over the past three months, signaling growing investor interest and building momentum. The company focuses on delivering affordable and accessible quantum solutions via its full-stack quantum platform, aiming to bridge the gap between quantum and classical computing.
While QUBT currently holds a Zacks Rank #3 (Hold) due to a lack of earnings estimate revisions in the past two months, the revenue outlook remains highly encouraging. Though still unprofitable, the company is expected to grow sales by 34% this year and an impressive 200% in 2026, suggesting a potential inflection point in its growth trajectory.
On the technical front, the stock is forming a tightening bullish flag pattern. If QUBT can break above key resistance at the $18.15 level, it could spark another strong rally and continue its recent streak of relative outperformance in the sector.
IonQ is one of the most well-known names in quantum computing, distinguished by its trapped-ion quantum technology and growing commercial traction. The company has secured strategic partnerships with tech giants like Microsoft Azure and Amazon Web Services, which are integrating IonQ's quantum capabilities into their cloud platforms. These collaborations not only validate IonQ's technology but also provide scalable pathways for adoption.
The stock currently holds a Zacks Rank #2 (Buy), supported by substantial upward revisions to its earnings outlook. Analysts have raised earnings estimates by 43% for the current year and 28% for 2026, clear signs of improving sentiment. Though IonQ remains unprofitable, its top-line growth is robust, with revenue expected to climb 97% this year and 57% next year.
From a technical standpoint, IONQ is forming a compressing bull flag pattern, a standard bullish continuation setup. If the stock can break above key resistance at $41.60, it should trigger a move toward new all-time highs, fueled by both momentum and the strength of its big-tech partnerships.
Quantum computing may still be in the early stages of commercialization, but investor enthusiasm is building fast, and with good reason. Technical progress is accelerating, enterprise adoption is growing, and Wall Street is beginning to recognize the long-term potential of the companies leading the charge.
Among the emerging players, D-WAVE QUNATUM, IonQ, and Quantum Computing Inc. each offer a unique angle on the quantum revolution, backed by impressive revenue growth forecasts, rising analyst sentiment, and powerful chart setups. While these stocks remain volatile and speculative, they are showing all the technical and fundamental traits of breakout candidates.
For investors willing to take on higher risk in pursuit of disruptive upside, these three quantum stocks are worth a close look as momentum continues to build in 2025.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
IonQ, Inc. (IONQ) : Free Stock Analysis Report
D-Wave Quantum Inc. (QBTS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
ACHV: Achieve's Busy Day
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.
Yahoo
11 minutes ago
- Yahoo
No Duh: Suze Orman on Why Parents Shouldn't Be Paying Their Adult Kids' Phone Bills
In one of the most famous — and funniest — scenes from the 2010s-era HBO comedy series 'Girls,' perpetually petulant slacker and aspiring 'voice of a generation' Hannah Horvath (Lena Dunham) sits across from her parents as they cut her off financially. While Hannah has spent hours at an unpaid internship, bopping around Brooklyn and discovering herself, Mom and Dad have been footing the bill for everything — including her phone. Up Next: For You: 'We can't keep bankrolling your groovy lifestyle,' Mom says, prompting Hannah to insist that she's so close to the life she wants, her parents shouldn't end it now. The scene resonates because it has played out thousands of times in households around the country. Suze Orman, personal finance expert and best-selling author, would likely support Hannah's parents in their choice to make her stand on her own two feet — even if she's generally more in favor of starting with small, gradual steps. In a recent LinkedIn post, Orman emphasized how important it is for parents to stop paying for even seemingly small expenses, like phone bills, to help their children become more financially independent. Orman understands why parents are so tempted to help young adults. After all, cell phone bills and streaming services seem like relatively minor expenses — so why not make your kids' lives easier by covering them? However, Orman urges parents to flip their perspective: If the amount is truly small, that's exactly why young adults should be paying it themselves. Learning to manage even modest bills helps build a strong financial foundation. 'If it's a manageable amount, it won't be hard for them to take on. And that's a key step toward financial independence,' Orman wrote. 'Maybe it's the first bill they put on auto-pay — helping them build responsible habits and a strong credit score. Every step counts on the road to financial freedom!' Learn More: Hannah's parents may have had the right idea, but forcing her into total financial independence without helping her establish a financial safety net first might not be the wisest approach. Orman isn't against parents offering some financial help to their adult children, but she believes it should be structured to help young adults develop financial skills. In addition to having young adults pay for their own phone bills, streaming services, and car insurance, Orman says that adult children who move back home should chip in toward household expenses. Parents don't need to charge their twentysomethings the equivalent of a full market-rate mortgage or rent payment — after all, if they could afford rent, they wouldn't be living at home — but getting them in the habit of budgeting a certain amount to make 'rent' each month helps instill financial discipline. If parents genuinely don't need the extra money, they can always set aside their child's 'rent payments' and later return the funds as the foundation for an emergency savings account. As your children become adults — goodness, where did the time go? — you're nearing the age where retirement planning becomes even more critical. To ensure your own future, you simply can't remain open as the Bank of Mom and Dad. Orman stresses that while parents should encourage their kids to build financial independence, they must also stay focused on their own financial goals — especially retirement. Think of it this way: You've worked hard to build your financial security, and just as your adult children are in their own self-discovery periods, you have the right to start one of your own. More From GOBankingRates 8 Common Mistakes Retirees Make With Their Social Security Checks This article originally appeared on No Duh: Suze Orman on Why Parents Shouldn't Be Paying Their Adult Kids' Phone Bills
Yahoo
12 minutes ago
- Yahoo
Trump Admin Insider Blows Lid Off Tariffs: ‘It's All Fake'
A source deeply embedded in the Trump administration's ongoing trade talks accused the Republican president of waging a tariff war for TV ratings. '[Donald] Trump knows the most interesting part of his presidency is the tariff conversation,' the White House insider, who chose to remain anonymous out of fear of reprisal, told Politico. 'It's all fake. There's no deadline. It's a self-imposed landmark in this theatrical show, and that's where we are.' In April, the MAGA figurehead paused his sweeping 'Liberation Day' tariffs to announce a three-month window for the world to negotiate new trade agreements with the United States—or face the full fury of his levies. In a subsequent interview with Time magazine, Trump claimed to have in principle already 'made all the deals' with more than 200 foreign partners, before later suggesting the real number would likely be closer to just a few dozen. Yet ahead of a self-imposed July 9 deadline, only the UK and China have inked relatively limited arrangements, with less than four days now left to go. As global markets brace for the Wednesday deadline, Trump has lately appeared full of tough talk in his public appearances, telling reporters Friday he'd already signed more than 12 'take it or leave it' letters to various countries reminding them of the levies they'll face if a deal is not soon reached, Reuters reported. On other occasions, Truymp appeared to revel in the uncertainty that his tariff regime has created. 'We can do whatever we want,' he said of the deadline during a White House press conference Tuesday, CNBC reported. 'We could extend it, we could make it shorter. I'd like to make it shorter.' That ambivalence apparently has some of the president's allies questioning just how far he's willing to go to net new trade opportunities for the country. 'You have wins. Take them,' as the White House insider put it to Politico. 'You only have to assume he doesn't want to take them because he likes the game too much.' In a statement to the Daily Beast, White House spokesman Kush Desai said 'the hollowing out of American Main Streets and industries by unfair foreign trade practices is not a theatrical show.' Desai added, 'President Trump pledged to use tariffs to level the playing field and restore American Greatness, and the Administration is committed to delivering on this pledge.'
